WASHINGTON — The Association for Accessible Medicines and the Biosimilars Council today congratulated George Francis Tidmarsh, M.D., Ph.D., on his appointment as Director of the Center for Drug Evaluation and Research at the U.S. Food and Drug Administration.
“Alongside our Biosimilars Council, AAM and its members welcome George Francis Tidmarsh, M.D., Ph.D., as the FDA's newest Director of the Center for Drug Evaluation and Research at the FDA," said John Murphy III, President and CEO of AAM. “Improving the health of patients through more timely access to lower-cost generic and biosimilar medicines is essential to the livelihood of America. We look forward to a collaborative partnership with Dr. Tidmarsh and the larger team at CDER to prioritize regulatory efficiency and help ensure the medicines that cost less and make up 90 percent of all prescriptions filled in the U.S. are always available for patients.”
AAM and the Biosimilars Council congratulate Dr. Tidmarsh and stand ready to support CDER’s continued success in advancing public health.
